Published in J Virol on February 01, 1998
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc Natl Acad Sci U S A (2005) 1.72
Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol (1999) 1.52
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35
Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol (2001) 1.17
Propagation of infectious human papillomavirus type 16 by using an adenovirus and Cre/LoxP mechanism. Proc Natl Acad Sci U S A (2004) 1.15
Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. Infect Immun (1998) 1.10
Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol (2003) 1.09
Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J Gen Virol (2001) 1.05
Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol (2001) 1.03
Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol (2001) 1.02
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol (2005) 0.98
Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. J Clin Microbiol (2002) 0.91
Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization. J Virol (2013) 0.87
HPV in HIV-Infected Women: Implications for Primary Prevention. Front Oncol (2014) 0.86
Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci (2009) 0.86
Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1. PLoS Pathog (2014) 0.82
Serological relationship between cutaneous human papillomavirus types 5, 8 and 92. J Gen Virol (2009) 0.82
Influence of physiologic folate deficiency on human papillomavirus type 16 (HPV16)-harboring human keratinocytes in vitro and in vivo. J Biol Chem (2012) 0.79
Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies. J Transl Med (2010) 0.77
A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays. Hum Vaccin Immunother (2015) 0.76
Replication interference between human papillomavirus types 16 and 18 mediated by heterologous E1 helicases. Virol J (2014) 0.75
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol (1988) 16.82
Human papillomavirus type 16 DNA sequence. Virology (1985) 9.44
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis (1994) 7.00
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol (1993) 4.00
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol (1993) 3.65
Human papillomavirus types 6 and 11 mRNAs from genital condylomata acuminata. J Virol (1987) 2.57
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol (1994) 2.52
Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol (1990) 2.34
Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol (1997) 2.29
Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol (1990) 2.26
Laboratory production in vivo of infectious human papillomavirus type 11. J Virol (1987) 2.20
Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology (1996) 2.08
Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts. Int J Cancer (1991) 1.98
Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol (1996) 1.94
A human papilloma virus type 11 transcript encoding an E1--E4 protein. Virology (1987) 1.76
Identification of a transforming gene of human papillomavirus type 16. J Virol (1989) 1.75
Antiviral therapy for human papillomaviruses: rational and prospects. Ann Intern Med (1995) 1.65
Epidemiology and partial nucleotide sequence of four novel genital human papillomaviruses. J Infect Dis (1994) 1.64
Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol (1994) 1.60
Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology (1996) 1.45
Identification and mapping of human papillomavirus type 1 RNA transcripts recovered from plantar warts and infected epithelial cell cultures. J Virol (1987) 1.44
Postattachment neutralization of papillomaviruses by monoclonal and polyclonal antibodies. Virology (1995) 1.40
Human papillomavirus type 1 produces redundant as well as polycistronic mRNAs in plantar warts. J Virol (1990) 1.31
Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse: detection of HPV-11 mRNAs. J Infect Dis (1992) 1.20
Neutralization of CRPV infectivity by monoclonal antibodies that identify conformational epitopes on intact virions. Virus Res (1991) 1.19
Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro. J Invest Dermatol (1995) 1.14
In vitro HPV-11 infection of human foreskin. J Invest Dermatol (1993) 1.10
Propagation of human papillomavirus type 11 in human xenografts using the severe combined immunodeficiency (SCID) mouse and comparison to the nude mouse model. Virology (1993) 1.09
Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse. J Virol (1998) 0.93
Strategy for typing human papillomaviruses by RFLP analysis of PCR products and subsequent hybridization with a generic probe. Biotechniques (1995) 0.84
A major transcript of human papillomavirus type 16 in transformed NIH 3T3 cells contains polycistronic mRNA encoding E7, E5, and E1--E4 fusion gene. Virus Genes (1990) 0.80
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A (1991) 6.13
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72
Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science (1997) 4.57
Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol (1993) 4.00
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 3.88
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol (1994) 3.33
Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. J Exp Med (1989) 3.03
Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med (1993) 2.96
Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. OFF. Genes Dev (1992) 2.90
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun (2001) 2.68
The Rapid Syndrome Validation Project (RSVP). Proc AMIA Symp (2001) 2.67
Studies on the electrical potential profile across rabbit ileum. Effects of sugars and amino acids on transmural and transmucosal electrical potential differences. J Gen Physiol (1971) 2.42
Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis (2000) 2.37
Genetic diversity of Borrelia burgdorferi in lyme disease patients as determined by culture versus direct PCR with clinical specimens. J Clin Microbiol (1999) 2.35
NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med (1991) 2.15
Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population. J Immunol (1990) 2.05
Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein. J Immunol (1990) 2.03
Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun (2001) 1.97
High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease. J Exp Med (1993) 1.97
Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. Ann Neurol (1995) 1.91
CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. Proc Natl Acad Sci U S A (1990) 1.88
The clinical and economic impact of deep chest surgical site infections following coronary artery bypass graft surgery. Chest (2000) 1.85
Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature (1994) 1.69
Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J Virol (1998) 1.67
Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology (1993) 1.60
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol (1994) 1.60
Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol (1997) 1.58
Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol (1994) 1.57
Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med (1994) 1.55
Rift Valley fever virus M segment: phlebovirus expression strategy and protein glycosylation. Virology (1989) 1.53
Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol (1999) 1.52
Logistic risk model for mortality following elective abdominal aortic aneurysm repair. Br J Surg (2011) 1.50
Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type 11 origin. J Virol (1993) 1.50
Cloning and characterization of a novel T cell activation gene. J Immunol (1987) 1.50
Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol (1998) 1.49
Use of glycerol-cryoprotected Lactobacillus casei for microbiological assay of folic acid. Clin Chem (1982) 1.46
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Immunological analyses of human papillomavirus capsids. Vaccine (2001) 1.40
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells. J Immunol (1991) 1.38
Electrical properties of isolated human gallbladder. Am J Physiol (1973) 1.37
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery (1990) 1.34
Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding. J Immunol (1988) 1.34
Survival in patients with the Zollinger-Ellison syndrome treated by total gastrectomy. Am J Surg (1966) 1.33
A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J Virol (1995) 1.33
Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology (1989) 1.33
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Surgical management of the Zollinger-Ellison syndrome. Surg Clin North Am (1974) 1.32
The influence of total gastrectomy on survival in malignant Zollinger-Ellison tumors. Ann Surg (1974) 1.31
Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J Immunol (1993) 1.30
3-Deoxy-d-arabino-Heptulosonate 7-Phosphate Synthase from Potato Tuber (Solanum tuberosum L.). Plant Physiol (1986) 1.28
Macrophage factor controlling differentiation of B cells. J Immunol (1979) 1.28
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis (1999) 1.24
Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes. J Exp Med (1992) 1.23
A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis (2001) 1.20
Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse: detection of HPV-11 mRNAs. J Infect Dis (1992) 1.20
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
Treatment of condyloma acuminatum with three different interferons administered intralesionally. A double-blind, placebo-controlled trial. Ann Intern Med (1988) 1.19
Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition. J Exp Med (1990) 1.17
Presentation of three different viral peptides, HTLV-1 Tax, HCMV gB, and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule. J Immunol (1992) 1.16
Nuclear import of HPV11 L1 capsid protein is mediated by karyopherin alpha2beta1 heterodimers. J Cell Biochem (1999) 1.16
Immunology of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. An update. Ann Intern Med (1987) 1.16
GM-2 gangliosidosis (Sandhoff's disease): two year follow-up by MRI. Neuroradiology (1994) 1.14
Search for a supersymmetric partner to the top quark in final states with jets and missing transverse momentum at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.13
Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells. Antiviral Res (1998) 1.13
Induction of phenotypic lymphocyte differentiation in LPS unresponsive mice by an LPS-induced serum factor and by lipid A-associated protein. J Immunol (1977) 1.13
B-cell activation by lipopolysaccharide. Distinct pathways for induction of mitosis and antibody production. J Exp Med (1977) 1.11
Evaluation of ascorbic acid in protecting labile folic acid derivatives. Proc Natl Acad Sci U S A (1983) 1.10
Immunophenotypic characterization of peripheral T lymphocytes in Mycobacterium tuberculosis infection and disease. Clin Exp Immunol (2002) 1.09
Propagation of human papillomavirus type 11 in human xenografts using the severe combined immunodeficiency (SCID) mouse and comparison to the nude mouse model. Virology (1993) 1.09
Use of human papillomavirus type 11 virions in an ELISA to detect specific antibodies in humans with condylomata acuminata. J Gen Virol (1991) 1.09
Two types of mutants affecting voltage-sensitive sodium channels in Drosophila melanogaster. Nature (1984) 1.08
Operative choledochoscopy. Results of a prospective study in several institutions. Am J Surg (1977) 1.07
Duodenal wall tumors and the Zollinger-Ellison syndrome. Surgical management. Arch Surg (1973) 1.07
Expression in Escherichia coli of seven DNA fragments comprising the complete L1 and L2 open reading frames of human papillomavirus type 6b and localization of the 'common antigen' region. J Gen Virol (1989) 1.07
Search for tb resonances in proton-proton collisions at √s=7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.07
Adenocarcinoma of the pancreas: detection of occult metastases in regional lymph nodes by a polymerase chain reaction-based assay. Cancer (1998) 1.07
Intraoperative biliary endoscopy. Arch Surg (1982) 1.05
Search for a light Higgs boson decaying to long-lived weakly interacting particles in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.05
Suppression and enhancement of the T cell-dependent production of antibody to SRBC in vitro by bacterial lipopolysaccharide. J Immunol (1975) 1.04
The Zollinger-Ellison syndrome updated. Surg Clin North Am (1967) 1.04
NIH conference. Development and evaluation of a vaccine for human immunodeficiency virus (HIV) infection. Ann Intern Med (1989) 1.04